Firstly, CHD prevalence in TSC1 and TSC2 patients in this cohort were determined, with 57% and 75% of patients respectively receiving a diagnosis of either single or multiple CR at some point during their lifetime, with no significant difference in rhabdomyoma prevalence between the two populations found (z = −1.56, p = 0.119) (Fig. 3A). The gene discussed is TSC1; the disease is rhabdomyoma.